La présentation est en train de télécharger. S'il vous plaît, attendez

La présentation est en train de télécharger. S'il vous plaît, attendez

Pr. Christophe Pison, MD, PhD Clinique Universitaire de Pneumologie Pole Thorax et Vaisseaux Inserm1050 Biologie Environnementale et Systémique - BEeSY.

Présentations similaires


Présentation au sujet: "Pr. Christophe Pison, MD, PhD Clinique Universitaire de Pneumologie Pole Thorax et Vaisseaux Inserm1050 Biologie Environnementale et Systémique - BEeSY."— Transcription de la présentation:

1 Pr. Christophe Pison, MD, PhD Clinique Universitaire de Pneumologie Pole Thorax et Vaisseaux Inserm1050 Biologie Environnementale et Systémique - BEeSY European Institute for Systems Biology and Medicine - EISBM CHU Grenoble Université Grenoble Alpes Systems Medicine of Respiratory Diseases an actual breakthrough INRIA, Lyon, 11 th of February 2014

2 2 Institut de Recherche Technologique

3 Consortium International Systemoscope « Repenser la recherche, comprendre le vivant, améliorer la santé »

4 Conflicts Of Interests, 3 last years Actélion Astra Zeneca Bayer Boehringer Ingelheim GlaxoSmithKline Lilly Novartis Nutricia-Danone Pfizer Gilead Therakos PneumRx, Medwin, Aeris, Holaira Vitalaire, Orkyn, SOS 4

5 Contents Non communicable diseases and health crisis Burden of respiratory diseases and unmet needs Systems medicine for respiratory health in Rhône-Alpes and Europe 5 Biotechnology Journal 2012; 7 special issue on Systems biology and personalized medicine

6 Non Communicable Diseases - NCDs 6

7 Health crisis Uncontrolled increase in health costs Efficacy Justice decline Increase incidence in Non Communicable Diseases - NCDs Limitations in present treatments and majors problems in new drug registrations New paradigms irruption « Exposome » & « Omics » data accumulation and how use it for better patient cares? Specialized versus Systems Medicine Reactive versus proactive Medicine? 7

8 Uncontrolled increases in health costs USA 18% GIP 2009 to 30% by 2030 & last OECD France, 12% GIP 2009, life expectancy 81 years in

9 Efficacy & Justice decline 9 NEJM 2010;362:460-5

10 5.2 million disability life years lost annually in the EU 300 billions / year in the EU Cystic fibrosis 1 st genetic lethal disease Asthma one of the most common chronic diseases in children COPD 4 th cause of death, 2 nd cause disability life year by 2008 in USA Lung cancer 1 st cause of death by cancer in men, 2 nd in women No cure for any! Burden of Respiratory Diseases and Unmet Needs 10

11 N Engl J Med 2013;369:

12 12 Prévention de la maladie Prédiction de la maladie Prédiction de la réponse M ÉDECINE 4P: L OPPORTUNITÉ Stratégies personnalisées et participatives Traitement ciblé

13 Agir là Changer le cours de la vie Ou la ? Changer le cours de la maladie Guérir Ou encore la ? Contrôler Thérapie ciblée Médecine systémique en pratique Hood L, RMMJ 2013 adapté du Pr. A. Magnan

14 Peter Hunter, University of Auckland – Denis Noble, Oxford University Challenge to integrate multi-scale space-time dimensions 14

15 Achilles' tendons in Lung Transplantation -15%, 3 months - 4% / year Shortage of grafts, Primary Graft Dysfunction Chronic Lung Allograft Dysfunction - CLAD BOS in 50% at 5 years different patterns 30% cause of death > 1 year median survival 1.5 years, if early onset 15

16 QALY - Quality Adjusted Life Years Résultats de la transplantation pulmonaire, S. Quêtant, T. Rochat, C. Pison. RMR 2010; 27: , Année Qualité de vie ajusté sur la survie 16

17 Signature to predict chronic dysfunction 17

18 Time CLAD prediction: The clock is always ticking! Transplantation Jul 27;86(2):

19 Roedder et al. Genome Medicine 2011;3:37

20 20 SysCLAD Progress Meeting. ENS de Lyon, FR. November 12th,

21 COLT French prospective cohort since centres + Bruxelles Swiss Transplant Cohort Study, STCS since 2008 in Lausanne- Genève, Zurich VIII-2013, : 1050 transplanted, 512 reached year 2, 215 year 3 Donors: day 0 clinics HLA lung tissue Recipients: before Tx, day-0 Tx, M6-M12 post LTx Clinics, e.CRF Pollution Blood: HLA, transcriptomics x 2, proteomics x 2, miRNA x 1, lymphocytes subpopulations, exome sequencing BAL: microbiote macrophages polarization, proteomics x 2 Outcomes: to predict year-3 as soon as year-1 Design Methods in SysCLAD 21

22 22

23 Air pollution model (Ineris) Collaboration with Ineris (National Institute for Industrial Environment and Risks) to get access to the up-to date national-wide exposure model with high spatial and temporal resolutions (1x1km) 23

24 Pulmonary microbiota and Alveolar macrophage polarization in Lung transplant recipients Pulmonary microbiota and Alveolar macrophage polarization in Lung transplant recipients Service de Pneumologie Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland Laboratory: Ben Marsland, PhD Eric Bernasconi, PhD Laboratory: Ben Marsland, PhD Eric Bernasconi, PhD Clinical supervision: Prof. Laurent Nicod Prof. John-David Aubert Clinical supervision: Prof. Laurent Nicod Prof. John-David Aubert Research coordination: Dr. Angela Koutsokera Research coordination: Dr. Angela Koutsokera Adapted from SciencePhotoLibrary 24

25 NEJM 2013,369:

26 Editorial Prediction of chronic lung allograft dysfunction: a systems medicine challenge Christophe Pison, Antoine Magnan, Karine Botturi, Michel Sève, Sophie Brouard, Benjamin J. Marsland, Florian Ernst, Tobias Paprotka, Kevin Deplanche, Andreas Fritz, Valérie Siroux, Jean-Pierre Boissel, Paul A. Corris, Charles Auffray, Laurent P. Nicod and the SysCLAD consortium Eur Respir J 2014, in press 26

27 SysCLAD Consortium 27 Cohort Of Lung Transplantation-COLT (associating surgeons; anaesthetists,-intensivists, physicians, research staff) Bordeaux: J. Jougon, J.-F. Velly; H. Rozé; E. Blanchard, C. Dromer; Bruxelles: M. Antoine, M. Cappello, M. Ruiz, Y. Sokolow, F. Vanden Eynden, G. Van Nooten; L. Barvais, J. Berré, S. Brimioulle, D. De Backer, J. Créteur, E. Engelman, I. Huybrechts, B. Ickx, T. J.C. Preiser, T. Tuna, L. Van Obberghe, N. Vancutsem, J.-L. Vincent; P. De Vuyst, I. Etienne, F. Féry, F. Jacobs, C. Knoop, J.L. Vachiéry, P. Van den Borne, I. Wellemans ; G. Amand, L. Collignon, M. Giroux; Grenoble: E. Arnaud-Crozat, V. Bach, P.-Y. Brichon, P. Chaffanjon, O. Chavanon, A. de Lambert, S. Guigard, K. Hireche, A. Pirvu, P. Porcu, R. Hacini ; P. Albaladejo, C. Allègre, D. Anglade, D. Bedague, P. Bouzat, E. Briot, O. Carle, M. Casez-Brasseur, D. Colas, G. Dessertaine, M. Durand, J. Duret, M.C. Fèvre, G. Francony, S. Gay, M.R Marino, D. Protar, D. Rehm, S. Robin, M. Rossi-Blancher, L. Saunier; P. Bédouch, A. Boignard, H. Bouvaist, A. Briault, B. Camara, S. Chanoine, M. Dubuc, S. Lantuéjoul, S. Quêtant, J. Maurizi, P. Pavèse, C. Pison, C. Saint-Raymond, N. Wion; C. Chérion; Lyon: R. Grima, O. Jegaden, J.-M. Maury, F. Tronc; C. Flamens, S. Paulus; J.-F. Mornex, F. Philit, A. Senechal, J.-C. Glérant, S. Turquier; D. Gamondes; L. Chalabresse, F. Thivolet-Bejui; C Barnel, C. Dubois, A. Tiberghien; Paris, Hôpital Européen Georges Pompidou: F. Le Pimpec- Barthes, A. Bel, P. Mordant, P. Achouh; V. Boussaud; R. Guillemain, D. Méléard, M.O. Bricourt, B. Cholley ; V. Pezella; Marseille: M. Adda, M. Badier, F. Bregeon, B. Coltey, X.B. DJourno, S. Dizier, C. Doddoli, N. Dufeu, H. Dutau, JM. Forel, JY. Gaubert, C. Gomez, M. Leone, A. Nieves, B. Orsini, L. Papazian L, C. Picard, M. Reynaud-Gaubert, A. Roch, JM. Rolain, E. Sampol, V. Secq, P. Thomas, D. Trousse; Yahyaoui M ; Nantes: O. Baron, P. Lacoste, C. Perigaud, J.C. Roussel; I. Danner, A Haloun A. Magnan, A Tissot; T. Lepoivre, M. Treilhaud; K. Botturi-Cavaillès, S. Brouard, R. Danger, J. Loy M. Morisset, M. Pain, S. Pares, D. Reboulleau, P.-J. Royer ; Hôpital Marie Lanelongue: P. Dartevelle, E. Fadel, S. Mussot, D. Fabre, O. Mercier; P. Viard, F. Stéphan; J. Cerrina, P. Hervé, J. Le Pavec, F. Le Roy Ladurie ; l. lamrani Paris Hôpital Bichat: Y. Castier, P. Cerceau, F. Francis, G. Lesèche; N. Allou, P. Augustin, S. Boudinet, M. Desmard, G. Dufour, P. Montravers ; O. Brugière, G. Dauriat, G. Jébrak, H. Mal, A. Marceau, A.-C. Métivier, G. Thabut ; B. Ait Ilalne; Strasbourg: P. Falcoz, G. Massard, N. Santelmo; G. Ajob, O. Collange O. Helms, J. Hentz, A. Roche; B. Bakouboula, T. Degot, A. Dory, S. Hirschi, S. Ohlmann-Caillard, L. Kessler, R. Kessler, A. Schuller; K. Bennedif, S. Vargas; Suresnes: P. Bonnette, A. Chapelier, P. Puyo, E. Sage; J. Bresson, V. Caille, C. Cerf, J. Devaquet, V. Dumans- Nizard, ML. Felten, M. Fischler, AG. Si Larbi, M. Leguen, L. Ley, N. Liu, G. Trebbia; S. De Miranda, B. Douvry, F. Gonin, D. Grenet, A.M. Hamid, H. Neveu, F. Parquin, C. Picard, A. Roux; F. Bouillioud, P. Cahen, M. Colombat, C. Dautricourt, M. Delahousse, B. DUrso, J. Gravisse, A. Guth, S. Hillaire, P. Honderlick, M. Lequintrec, E. Longchampt, F. Mellot, A. Scherrer, L. Temagoult, L. Tricot; M. Vasse, C. Veyrie, L. Zemoura; Toulouse: J. Berjaud, L. Brouchet, M. Dahan; F. Le Balle, O. Mathe ; H. Benahoua, A. Didier, A.L. Goin, M. Murris; L. Crognier, O. Fourcade. Swiss Transplant Cohort Study-STCS Genève-Lausanne: T. Krueger, H.B. Ris, J.H. Robert, J. Wellinger; J.-D. Aubert, C. Blanc L.P. Nicod, B.J. Marsland, T. Rochat, P. Soccal; Ph Jolliet, A Koutsokera, C. Marcucci, O. Manuel; E. Bernasconi, M. Chollet, F. Gronchi, B. Marsland; Zurich: S. Hillinger, I. Inci, P. Kestenholz, W. Weder; M. Zalunardo; C. Benden, U. Buergi, L.C. Huber; B. Isenring, T. Rechsteiner, M. Schuurmans; T. Muller, A. Gaspert, D. Holzmann, N. Müller, S. Nicca, C. Schmid. SME and Platforms Biomax, Germany: A. Fritz, D. Maier; Finovatis, Lyon, France: K. Desplanche, D. Koubi; GATC, Germany: T. Paprotka, F. Ernst, B. Wahl; Novasdicovery, Lyon, France: J.-P. Boissel, G. Olivera-Botello; Prométhée Proteomics Platform, CHU Grenoble: C. Trocmé, B. Toussaint, S. Bourgoin-Voillard, M. Séve; Inserm U823, Université Joseph Fourier, Grenoble, France: M. Benmerad, V. Siroux, R. Slama; European Institute for Systems Biology & Medicine: C. Auffray, D. Charron, J. Pellet, C. Pison

28 Respiratory Systems Medicine - ReSyM Objectives build a multidisciplinary network to define within 2 years 3 use cases of systems biology / medicine in the context of respiratory medicine, using preexisting set of data successfully apply to European frame programme Horizon

29 29

30 Long-life dimension repeated measurements to refine phenotypes Adapted from R. Slama group Basic Clinical and Biomedical Questions 30

31 Basic Clinical and Biomedical Questions Mechanisms Shared and non-shared mechanisms in COPD-Asthma / Lung Cancer / Interstitial Pulmonary Fibrosis Respective weights of risk factors to develop a specific chronic respiratory disease: Environmental factors [pollution, smoking, physical activity, nutrition, stress, sleep] Age, Gender, Socio-economic class and Occupation Genetic susceptibility 31

32 Taxonomy New classification of old diseases as Asthma, COPD, Lung fibrosis, Lung cancer Associations with other chronic respiratory conditions: Asthma-COPD COPD-Lung Cancer Emphysema-IPF IPF-Lung Cancer Association with other chronic conditions: mainly cardiovascular and metabolic chronic diseases Basic Clinical and Biomedical Questions 32

33 33

34 Clinique Universitaire de Pneumologie Université Grenoble Alpes Oncologie Thoracique IRC Mucoviscidose HTAP Transplantation Maladies Chroniques Respiratoires 34 Promouvoir Bien-Etre Médecine 4P Mécanismes communs maladies chroniques respiratoires et cancer bronchqiue (miRNA, épigénétiques, effet Warburg), patients communs, technologies communes, approches systémiques Proportion de patients pris en charge Médecine reactive type CHU Coûts efficacité Médecine pro-active

35

36 Biologie des Systèmes Médecine 4P Biologie Technologie Signatures complexes Biomarqueurs Intégration des données Modélisation Prédiction Prévention Personnalisation Participation Adapté du Pr. A. Magnan 36


Télécharger ppt "Pr. Christophe Pison, MD, PhD Clinique Universitaire de Pneumologie Pole Thorax et Vaisseaux Inserm1050 Biologie Environnementale et Systémique - BEeSY."

Présentations similaires


Annonces Google